KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities (2020 - 2025)

Historic Other financing activities for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $13.5 million.

  • Royalty Pharma's Other financing activities rose 33856.87% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 20719.62%. This contributed to the annual value of $12.6 million for FY2024, which is 69047.62% up from last year.
  • As of Q3 2025, Royalty Pharma's Other financing activities stood at $13.5 million, which was up 33856.87% from $300000.0 recorded in Q4 2024.
  • Royalty Pharma's 5-year Other financing activities high stood at $13.5 million for Q3 2025, and its period low was $300000.0 during Q4 2024.
  • Its 5-year average for Other financing activities is $4.7 million, with a median of $1.6 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Other financing activities surged by 43046.36% in 2021 and then crashed by 8120.3% in 2024.
  • Over the past 5 years, Royalty Pharma's Other financing activities (Quarter) stood at $801000.0 in 2021, then soared by 68.16% to $1.3 million in 2022, then grew by 18.49% to $1.6 million in 2023, then crashed by 81.2% to $300000.0 in 2024, then soared by 4414.33% to $13.5 million in 2025.
  • Its Other financing activities was $13.5 million in Q3 2025, compared to $300000.0 in Q4 2024 and $3.1 million in Q3 2024.